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Abstract
Cholecystokinin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on CCK receptors
[89]) are activated by the endogenous peptides cholecystokinin-8 (CCK-8), CCK-33, CCK-58 and gastrin
(gastrin-17). There are only two distinct subtypes of CCK receptors, CCK1 and CCK2 receptors [63, 123], with
some alternatively spliced forms most often identified in neoplastic cells. The CCK receptor subtypes are
distinguished by their peptide selectivity, with the CCK1 receptor requiring the carboxyl-terminal heptapeptide-
amide that includes a sulfated tyrosine for high affinity and potency, while the CCK2 receptor requires only the
carboxyl-terminal tetrapeptide shared by each CCK and gastrin peptides. These receptors have characteristic
and distinct distributions, with both present in both the central nervous system and peripheral tissues.
Contents
This is a citation summary for Cholecystokinin receptors in the Guide to Pharmacology database (GtoPdb). It
exists purely as an adjunct to the database to facilitate the recognition of citations to and from the database by
citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are
given here under database links.
GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a
reference work which is most usefully represented as an on-line database. As in any publication this work
should be appropriately cited, and the papers it cites should also be recognized. This document provides a
citation for the relevant parts of the database, and also provides a reference list for the research cited by those
parts.
Please note that the database version for the citations given in GtoPdb are to the most recent preceding version
in which the family or its subfamilies and targets were substantially changed. The links below are to the current
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